Table.

Day 45 and day 180 outcomes for the anti-coronavirus therapy trials

		Inpatient trial (n=2749)†		Outpatient trial (n=3917)
		Colchicine vs control	Rivaroxaban plus aspirin vs control	Colchicine vs control	Aspirin vs control
Primary outcome		Ventilation, high-flow oxygen, or death	Major thrombosis, ventilation, high-flow oxygen, or death	Hospitalisation or death	Major thrombosis, hospitalisation, or death
Day 45
	Patients with events	725 (27·8%)	582 (27·5%)	131 (3·4%)	132 (3·4%)
	HR	1·04 (0·90–1·21)	0·92 (0·78–1·09)	1·02 (0·72–1·43)	0·80 (0·57–1·13)
Day 180*
	Patients with events	734 (28·1%)	589 (27·8%)	145 (3·7%)	146 (3·8%)
	HR	1·06 (0·92–1·23)	0·93 (0·79–1·10)	1·10 (0·80–1·53)	0·84 (0·61–1·17)
Patients with first events between day 45 and day 180*		3 per 1000	3 per 1000	3 per 1000	4 per 1000

Data are n (%) or HR (95% CI). HR=hazard ratio.

^*A total of 78 patients were lost to follow-up or withdrew consent prior to the final visit.

^†1981 patients participated in both randomisations, 630 participated only in the colchicine vs control randomisation and 130 participated only in the rivaroxaban plus aspirin vs control randomisation.